PTGX — Protagonist Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.58bn
- $1.23bn
- $60.00m
- 55
- 13
- 95
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 87.97 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.68 | ||
| Price to Tang. Book | 4.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 26.26 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.82% | ||
| Return on Equity | -28.59% | ||
| Operating Margin | -156.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.23 | 28.63 | 27.36 | 26.58 | 60 | 152.5 | 137.5 | 14.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Directors
- Harold Selick NEC (66)
- Dinesh Patel PRE (64)
- Donald Kalkofen CFO (57)
- David Liu CSO (70)
- Suneel Gupta OTH (63)
- Samuel Saks OTH (66)
- Bryan Giraudo IND (45)
- Sarah Noonberg IND (53)
- Sarah O'Dowd IND (71)
- William Waddill IND (64)
- Lewis Williams IND (71)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 22nd, 2006
- Public Since
- August 11th, 2016
- No. of Shareholders
- 2
- No. of Employees
- 112
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 58,274,998
- Address
- 7707 Gateway Blvd Ste 140, NEWARK, 94560-1160
- Web
- https://www.protagonist-inc.com/
- Phone
- +1 5104740170
- Contact
- Jami Taylor
- Auditors
- Ernst & Young LLP
Upcoming Events for PTGX
Protagonist Therapeutics Inc Annual Shareholders Meeting
Protagonist Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Protagonist Therapeutics Inc Earnings Release
Similar to PTGX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Protagonist Therapeutics share price?
As of Today at 19:17 UTC, shares in Protagonist Therapeutics are trading at $27.04. This share price information is delayed by 15 minutes.
How has the Protagonist Therapeutics share price performed this year?
Shares in Protagonist Therapeutics last closed at $27.04 and the price had moved by +38.6% over the past 365 days. In terms of relative price strength the Protagonist Therapeutics share price has outperformed the S&P500 Index by +11.93% over the past year.
What are the analyst and broker recommendations for Protagonist Therapeutics?
The overall consensus recommendation for Protagonist Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Protagonist Therapeutics dividend yield?
Protagonist Therapeutics does not currently pay a dividend.
Does Protagonist Therapeutics pay a dividend?
Protagonist Therapeutics does not currently pay a dividend.
When does Protagonist Therapeutics next pay dividends?
Protagonist Therapeutics does not currently pay a dividend.
How do I buy Protagonist Therapeutics shares?
To buy shares in Protagonist Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Protagonist Therapeutics?
As of the previous close price of $27.04, shares in Protagonist Therapeutics had a market capitalisation of $1.58bn.
Where are Protagonist Therapeutics shares listed?
Here are the trading details for Protagonist Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: PTGX
What kind of share is Protagonist Therapeutics?
Based on an overall assessment of its quality, value and momentum Protagonist Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Protagonist Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Protagonist Therapeutics is $44.20. That is 63.46% above the last closing price of $27.04.
Analysts covering Protagonist Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $0.75 for the next financial year.
What is the trend in the Protagonist Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Protagonist Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +49.5%.
As of the last closing price of $27.04, shares in Protagonist Therapeutics were trading +24.39% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Protagonist Therapeutics PE Ratio?
The Protagonist Therapeutics PE ratio based on its reported earnings over the past 12 months is 87.97. The shares last closed at $27.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Protagonist Therapeutics?
Protagonist Therapeutics' management team is headed by:
- Harold Selick - NEC
- Dinesh Patel - PRE
- Donald Kalkofen - CFO
- David Liu - CSO
- Suneel Gupta - OTH
- Samuel Saks - OTH
- Bryan Giraudo - IND
- Sarah Noonberg - IND
- Sarah O'Dowd - IND
- William Waddill - IND
- Lewis Williams - IND